HOME >> MEDICINE >> NEWS
NIAID Ebola vaccine enters human trial

quency.

On November 17, 2003, the World Health Organization reported 11 cases of Ebola hemorrhagic fever in the Republic of the Congo. Dr. Nabel notes, "The current Ebola outbreak in the Congo provides a stark reminder of the need to rapidly develop vaccines against such perilous infections. A few years ago, we did not imagine that our vaccine would enter human trials so quickly, but the re-emergence of such viruses makes it all the more important to respond quickly. Individuals who volunteer for these vaccine trials can help us understand if our new vaccines ultimately will be effective."

Twenty-seven volunteers between the ages of 18 and 44 will participate in the study. Six people will receive a placebo injection and 21 will receive the investigational vaccine, manufactured by Vical Inc., a San Diego biotechnology company working in collaboration with the VRC. Vical has also secured a nonexclusive license from NIH to proprietary gene sequences used in the DNA Ebola vaccine. In the new trial, volunteers will receive three injections over two months and will be followed for one year. Volunteers will not be exposed to Ebola virus. Individuals interested in enrolling in the trial may visit http://www.clinicaltrials.gov or call the VRC toll-free at 1-866-833-LIFE (5433).

The candidate vaccine is synthesized using modified, inactivated genes from Ebola virus. This gives the immune system information about viral structures so that it can mount a rapid defense should the real virus ever be encountered. There is no infectious material in the vaccine, and the virus was not present during any stage of the manufacturing process, notes Barney Graham, M.D., Ph.D., director of the clinical trials unit of the VRC. "It is impossible for the vaccine to cause infection," he adds, "because it employs new technology known to safely stimulate broad immune responses."

Besides assessing the vaccine's safety, re
'"/>

Contact: Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
18-Nov-2003


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIAID Ebola vaccine enters human trial

(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and amputation , AUGUST 3, 2015 – Since winning a South by Southwest® ... Not Impossible – an organization whose mission is to develop technology for the ...
(Date:8/3/2015)... ... 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and ... Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker ... the Company’s presentation may be accessed via the investor relations section of the Company’s ...
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Sorrento ... that it has entered into an exclusive licensing agreement ... or biobetter antibodies from Mabtech Limited, a holding company ... China . Under the ... these 4 monoclonal antibodies (mAbs) for the North American, ...
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... MOUNT PROSPECT, Ill. , July 31, 2015 ... of Pharmacy ® (NABP ® ) issued ... charged with ensuring that action is taken against ... the Internet Drug Outlet Identification Program ... 2015 , thousands of websites ...
Breaking Medicine Technology:Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3
Cached News: